AML-437: Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia
| Autor: | Maria Luna-Gonzalez, Angela María Peña, Maria Fernanda Ortiz, Manuel Rosales, Sara Ines Jimenez, Xueyi Chen, Miguel Sanz Alonso, Luis Antonio Salazar, Daniela Vasquez, Claudia Sossa, Pau Montesinos, Miguel Ochoa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Acute leukemia Secondary leukemia business.industry Myeloid leukemia Context (language use) Hematology University hospital Oncology hemic and lymphatic diseases Internal medicine Etiology medicine Secondary Acute Myeloid Leukemia In patient business neoplasms |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 21:S311-S312 |
| ISSN: | 2152-2650 |
| Popis: | Context: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Objective: To determine the OS of patients diagnosed with AML according to the type of AML, de novo (n-AML) or secondary (s-AML), in the Clinica Foscal, a university hospital in Colombia during 2013–2020. Results: A total of 157 patients were registered; 50.3% were male; the median age at the time of diagnosis was 58.8 years (range: 18–95); for n-AML median age was 57.4 years (range: 18–95), and 62.3 years (range: 26–84) for s-AML. Regarding the etiology of AML, 75.2% presented n-AML and 24.8% s-AML, distributed as follows: 23.1% secondary to chronic myeloproliferative neoplasms, 10.3% to therapy, and 4% to myelodysplasia. In patients with n-AML, 74.3% were classified as ECOG Conclusions: Our results demonstrated worse outcomes for patients with s-AML compared with patients with n-AML. It is important to identify s-AML patients and review their genetic and molecular expressions, so a directed treatment can be offered with major effectivity and early allogeneic transplant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect